Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Am J Transplant ; 22(12): 3146-3149, 2022 12.
Article in English | MEDLINE | ID: mdl-36131641

ABSTRACT

While euthanasia has been legalized in a growing number of countries, organ donation after euthanasia is only performed in Belgium, the Netherlands, Spain, and Canada. Moreover, the clinical practice of heart donation after euthanasia has never been reported before. We describe the first case of a heart donated after euthanasia, reconditioned with thoraco-abdominal normothermic regional perfusion, preserved using cold storage while being transported to a neighboring transplant center, and then successfully transplanted following a procurement warm ischemic time of 17 min. Heart donation after euthanasia using thoraco-abdominal normothermic regional perfusion is feasible, it could expand the heart donor pool and reduce waiting lists in countries where organ donation after euthanasia can be performed.


Subject(s)
Euthanasia , Heart Transplantation , Tissue and Organ Procurement , Humans , Organ Preservation , Perfusion , Tissue Donors , Death
3.
Ann N Y Acad Sci ; 1110: 248-55, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17911439

ABSTRACT

Multifocal motor neuropathy is a distinct entity, whose treatment differs from that of other chronic immune-mediated neuropathies, mainly chronic inflammatory demyelinating polyradiculoneuropathy, and its variant, multifocal acquired demyelinating sensory and motor neuropathy, although they share some electrophysiological characteristics. From the first descriptions, intravenous immunoglobulins (IVIg) have been considered to be the gold standard of treatment for multifocal motor neuropathy. However, if the effectiveness of IVIg has been confirmed by several randomized, double-blind, placebo-controlled trials, only a few patients experience persistent improvement after a single or few courses of therapy, and the long-term efficacy of IVIg in this disease is currently debated. Consequently, there is a need for new therapeutic strategies that focus on the effects and the costs of this therapy over long-term follow-up.


Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Polyneuropathies/immunology , Polyneuropathies/therapy , Clinical Trials as Topic , Humans , Immunotherapy , Polyneuropathies/pathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...